Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.
about
Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activityCD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tractPrimary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tractSpirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitroPreclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.CCR5 antagonism in HIV infection: current concepts and future opportunitiesA novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivoA highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS modelVaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmissionThe benzamide derivative N-[1-(7-tert-Butyl-1H-indol-3-ylmethyl)-2-(4-cyclopropanecarbonyl-3-methyl-piperazin-1-yl)-2-oxo-ethyl]-4-nitro-benzamide (SP-10) reduces HIV-1 infectivity in vitro by modifying actin dynamics.A decline in CCL3-5 chemokine gene expression during primary simian-human immunodeficiency virus infection.Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge.Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytesEarly divergent host responses in SHIVsf162P3 and SIVmac251 infected macaques correlate with control of viremia.Age-dependent role for CCR5 in antiviral host defense against herpes simplex virus type 2Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.High beta-chemokine expression levels in lymphoid tissues of simian/human immunodeficiency virus 89.6-vaccinated rhesus macaques are associated with uncontrolled replication of simian immunodeficiency virus challenge inoculum.CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.Dualtropic CXCR6/CCR5 Simian Immunodeficiency Virus (SIV) Infection of Sooty Mangabey Primary Lymphocytes: Distinct Coreceptor Use in Natural versus Pathogenic Hosts of SIVPreclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.Direct measurement of thermal stability of expressed CCR5 and stabilization by small molecule ligands.Attachment and fusion inhibitors potently prevent dendritic cell-driven HIV infectionA simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy.One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidatesSIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaquesA Chinese rhesus macaque (Macaca mulatta) model for vaginal Lactobacillus colonization and live microbicide development.A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge.Preexposure prophylaxis for HIV prevention.HIV transmission: closing all the doors.HIV-1 entry inhibitors: closing the front door.HIV-1 antiretroviral drug therapy.CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3).Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture.Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue.Transcriptional profiling of experimental CD8(+) lymphocyte depletion in rhesus macaques infected with simian immunodeficiency virus SIVmac239Multiple roles for chemokines in the pathogenesis of SIV infectionPharmacokinetic and Pharmacodynamic Evaluation following Vaginal Application of IQB3002, a Dual-Chamber Microbicide Gel Containing the Nonnucleoside Reverse Transcriptase Inhibitor IQP-0528 in Rhesus Macaques.
P2860
Q21562543-6E9C16F2-BA0B-4E56-BC83-37092B572DF4Q22242965-D1FCB459-F092-40DB-AFB0-BF4EA6F4942EQ22242981-9F7273AA-B783-41E8-95BF-7B80683A6689Q24563937-8D913C8F-C97A-41D1-AD8E-DD48E70AB5EFQ24812967-EEC4CC47-0188-4D78-ABFD-F05DA7845B47Q26865457-9A96CAEE-3489-49E9-B342-9A6F54878ADBQ27313759-F8233737-88BF-4750-B0BD-22BD448D6172Q27344720-E6EFB17F-AFF9-47C0-8698-D76427520E5FQ33245411-B61D175A-B4D0-42EE-A810-BD23AABE849BQ33270152-037B3151-F265-44AD-8439-D49C726431E5Q33293538-86A6499E-9A48-47F5-A700-00BABDE3B593Q33680650-1F40FC50-B40D-45EA-BA38-2567D5BEC052Q33716586-A484C7FF-D60B-4FEC-98E4-5709FAF65E27Q33862618-D449BE19-6964-471C-ACB5-3E8C3717A1E6Q33908877-7377B5B3-A8E5-43C3-8B52-D6F9F2B1A234Q33961704-E951CA61-B965-46E6-8CF0-030692EBA9E1Q34192490-FECB041C-9398-48DB-94D9-984522E95EB4Q34473072-101BD81B-F2AB-41F1-B357-31EFD0D0FEEFQ34482304-76067F69-0B15-44F1-904F-CE60E97FDD7EQ34510719-826A22C8-01F2-4E86-9575-F4A356E4F535Q34571010-A752A105-C8DA-41E9-8929-70A47AA1FFBFQ34574462-F9B1432D-20D2-4958-8C9B-2DF4656A6301Q34990151-A2A0D921-92E1-4151-BE76-4BF726FF017AQ35140303-63AF97C2-3636-4D93-826A-717B0FEBBA03Q35143735-7C0C578E-2E76-467C-9DAB-36CA3F82539CQ35575950-43875C19-E788-4559-B425-A3D751A7968EQ35667426-7D846281-123F-4540-A046-20F5E6727BBCQ35717688-65FB2EC4-E622-4A31-9064-0499F8820C60Q35743991-857AC400-9A40-4D45-B738-0739F2E567B5Q35753350-81B520C5-26EF-4BAF-9A5A-A80D495DD290Q35853012-7ED9707F-0BC4-4FF7-9CF9-FCA92FBCD3A7Q35956560-865B9C40-2D4F-45CB-B3CC-946A91908E30Q35963420-314E2853-64CD-476D-8B16-2E638F3CC369Q36105943-F4F5F134-E4E6-4966-9992-5311ACFC02A5Q36113575-DAB1E785-65B0-40DF-9884-ADF6765940E5Q36296739-AD9A6E8B-A779-4E86-B2D3-8931D70884BCQ36399466-7089E117-36C4-4DA6-9D96-7A1AC3975C0AQ36506883-955D1AD5-1AF7-460D-B5E0-C32C70B32FD8Q36634172-B15C092C-78A2-47AC-BD55-6E28054F0DFBQ36644657-12F0D9EC-E5A9-4B32-B546-CA199B0F1B4C
P2860
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Use of a small molecule CCR5 i ...... unodeficiency virus infection.
@ast
Use of a small molecule CCR5 i ...... unodeficiency virus infection.
@en
type
label
Use of a small molecule CCR5 i ...... unodeficiency virus infection.
@ast
Use of a small molecule CCR5 i ...... unodeficiency virus infection.
@en
prefLabel
Use of a small molecule CCR5 i ...... unodeficiency virus infection.
@ast
Use of a small molecule CCR5 i ...... unodeficiency virus infection.
@en
P2093
P2860
P50
P356
P1476
Use of a small molecule CCR5 i ...... munodeficiency virus infection
@en
P2093
Jacqueline D Reeves
Jason Dufour
Jeffrey D Lifson
John P Moore
Julie A DeMartino
Kathy Lyons
Kevin Kunstman
Martin S Springer
Michael Piatak
Per Johan Klasse
P2860
P304
P356
10.1084/JEM.20031266
P407
P577
2003-11-01T00:00:00Z